Vertex finished out 2021 strong, smashing analyst’s sales expectations for the full year. Chalk it up to the company’s entrenched position in cystic fibrosis, where Vertex expects to maintain its lead ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2021 and provided full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback